-

Volastra Therapeutics Announces Participation in 2022 Guggenheim Synthetic Lethality Day

NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN) as a vulnerability for cancer cells, today announced that members of its management team are scheduled to participate in a fireside chat at the 2022 Guggenheim Synthetic Lethality Day on May 16th at 11:30 a.m. ET.

A live webcast of the fireside chat can be accessed in the News and Views section of the company’s website at https://www.volastratx.com/news/. A replay of the webcast will be archived on the company’s website for 90 days.

About Volastra Therapeutics, Inc.

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is rapidly developing and implementing new methods to exploit this vulnerability. Leveraging its proprietary CINtech platform, the company is advancing a novel synthetic lethal and immune activating pipeline. Volastra’s lead program targets KIF18A, a mitotic kinesin, with first-in-human studies anticipated to start in early 2023.

For more information, please visit volastratx.com.

Contacts

Media
Lisa Qu
LQu@tenbridgecommunications.com

Industry:

Volastra Therapeutics

Release Versions
English

Contacts

Media
Lisa Qu
LQu@tenbridgecommunications.com

More News From Volastra Therapeutics

Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023

NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today released preclinical data from the company’s portfolio of KIF18A inhibitors at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando. Volastra’s KIF18A portfolio consists of two clinical-stage highly differentiated, novel, first-in-class KIF18A inhibitors: recently in-licensed sovilnesib (formally AMG650) and inte...

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

NEW YORK--(BUSINESS WIRE)--Funding supports clinical development of portfolio of KIF18A inhibitors and advancement of robust pipeline targeting chromosomally unstable cancers....

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech’s 2022 “Fierce 15,” designating it as one of the most promising early-stage biotechnology companies in the industry. “It is an honor and tremendous validation of our team and progress to be among the Fierce 15,” said Charles Hugh-Jones, M.D., FRCP, Chief Executive Officer at Volastra. “Our unique understan...
Back to Newsroom